Labcorp reported a 6.9% increase in Q3 2026 revenue to $3.81 billion and 14.5% growth in adjusted EPS, prompting an increase in full-year guidance and the approval of a new melanoma companion diagnostic.
Labcorp reported a 6.9% increase in Q3 2026 revenue to $3.81 billion and 14.5% growth in adjusted EPS, prompting an increase in full-year guidance and the approval of a new melanoma companion diagnostic.